Abstract
6716 Background: NK/T-cell lymphoma is a specific type of T-cell lymphoma which is prevalent in Eastern Asia and known to have poor prognosis. With the hope of better treatment outcome, we developed new induction regimen using dose-escalated doxorubicin and cyclophosphamide, and higher dose-intensity. Methods: Newly diagnosed, modified Ann-Arbor stage I and II, NK-T cell lymphoma patients were enrolled. We planned to treat them with 2 cycles of dose-intensive CHOP (DI-CHOP), followed by radiation (total 40 Gy with 20 fractions) and 4 cycles of conventional CHOP. DI-CHOP consisted of cyclophosphamide (1250 mg/m2, day 1), doxorubicin (75 mg/m2, day 1), vincristine (1.4 mg/m2, day 1) and prednisolone (100 mg/day for 5 days) with growth factor support (G-CSF 150 ug/day for 10 days). The second cycle of DI-CHOP was started as soon as possible when ANC more than 1500/uL and platelet count more than 75,000/uL no less than 14 days since day 1 of the first cycle. Results: From March 2000 to May 2003, consecutive 1...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
